Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.
Curaleaf Q1 Revenue Growth Stalls
First quarter 2024 revenue of $339 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48% First quarter 2024 adjusted EBITDA(1) of